Mutations in ARID1A lead to the redistribution of enhancer-associated marks such as H3K27ac and H3K4me1, significantly increasing the expression of oncogenes (e.g., MYC, CCND1) and inflammation-related genes (e.g., IL6, TNFα), which accelerates tumor growth and facilitates immune evasion through tumor microenvironment remodeling [186, 187]. The gene discussed is MYC; the disease is neoplasm.